四价脑膜炎球菌破伤风类毒素结合疫苗在≥56岁人群中的免疫原性与安全性:III期随机研究
本研究为III期随机非劣效试验,在≥56岁人群中比较MenACYW-TT与MPSV4的免疫原性和安全性。结果显示MenACYW-TT对A、C、W、Y四个血清群的血清应答均非劣于MPSV4,且hSBA滴度≥1:8的参与者比例更高,两种疫苗均未发现安全性问题。
要点
- MenACYW-TT在≥56岁人群中免疫应答非劣于MPSV4。
- 接种后30天,MenACYW-TT组各血清群hSBA滴度≥1:8比例更高。
- 两种疫苗均耐受良好,未发现安全性问题。
核心结论
- MenACYW-TT在≥56岁人群中耐受良好且具有免疫原性,有望替代MPSV4用于该年龄组。
研究设计与样本
- III期、改良双盲、随机、非劣效性研究(NCT02842866),在美国和波多黎各35个临床中心开展。
- ≥56岁个体随机接种单剂MenACYW-TT(n=451)或MPSV4(n=455),第0天接种。
- 采用人补体血清杀菌试验(hSBA)和幼兔补体血清杀菌试验(rSBA)检测基线及第30天针对A、C、W、Y血清群菌株的抗体。
- 安全性数据收集至接种后6个月。
主要发现
- MenACYW-TT对A、C、W、Y血清群的血清应答率分别为58.2%、77.1%、62.6%、74.4%,MPSV4分别为42.5%、49.7%、44.8%、43.4%。
- 第30天hSBA滴度≥1:8的比例:MenACYW-TT组为77.4%–91.7%,MPSV4组为63.1%–84.2%。
- 两种疫苗均未发现安全性问题。
临床怎么用
- 对于≥56岁人群,MenACYW-TT可作为MPSV4的替代选择,提供更优的免疫应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Invasive meningococcal disease has a high mortality rate in individuals aged ≥56 years, but no vaccine is currently licensed in the USA for this age group. This study assessed the safety and immunogenicity of an investigational quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACYW-TT) compared with a meningococcal quadrivalent polysaccharide vaccine (MPSV4) in this age group. METHODS: This was a Phase III, modified double-blind, randomized, non-inferiority study (NCT02842866) across 35 clinical sites in the USA and Puerto Rico in individuals aged ≥56 years. A single dose of the MenACYW-TT (n = 451) or MPSV4 vaccine (n = 455) was administered on Day 0. A serum bactericidal assay with human (hSBA) and baby rabbit (rSBA) complement was used to measure antibodies against serogroups A, C, W, and Y test strains at baseline and Day 30. Safety data were collected up to six months post-vaccination. RESULTS: The seroresponse to MenACYW-TT was non-inferior to MPSV4 for each of the serogroups (A: 58.2% vs. 42.5%; C: 77.1% vs. 49.7%; W: 62.6% vs. 44.8%, Y: 74.4% vs. 43.4%, respectively). At Day 30, participants achieving hSBA titers ≥1:8 were higher for all serogroups after MenACYW-TT vs. MPSV4 (77.4-91.7 vs. 63.1-84.2%, respectively). No safety concerns were identified for either vaccine. CONCLUSION: MenACYW-TT was well-tolerated and immunogenic in ≥56-year-olds, offering the potential to replace MPSV4 in this age group.
引用
- Esteves-Jaramillo A, Koehler T, Jeanfreau R, et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in ≥56-year-olds: A Phase III randomized study. Vaccine. 2020. PMID: 32387012. doi:10.1016/j.vaccine.2020.04.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。